Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bezacitinib - Hangzhou Biosun Pharmaceutical

Next Previous
Drug Profile

Bezacitinib - Hangzhou Biosun Pharmaceutical

Alternative Names: OB-756

Latest Information Update: 06 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hangzhou Biosun Pharmaceutical
  • Class Acetonitriles; Amines; Antihaemorrhagics; Antineoplastics; Antirheumatics; Piperidines; Pyrazoles; Pyrimidines; Pyrroles; Small molecules; Sulfones
  • Mechanism of Action Janus kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Myelofibrosis
  • Phase III Polycythaemia vera
  • Phase I/II Essential thrombocythaemia; Graft-versus-host disease
  • Phase I Rheumatoid arthritis

Most Recent Events

  • 06 May 2026 Chemical structure information added
  • 06 May 2026 Hangzhou Biosun Pharmaceutical announces intention to submit NDA to the NMPA for Polycythemia vera in Q3 2026
  • 06 May 2026 Ad hoc: Drug review: Introduction modified. KDM rearranged. Approval information added. Candidate specific code not available. DevT corrected. Redundant FEs mark were completed. orgT checked. CTR trials added. emailed CT team to create CTP. Science data corrected. although data is for phase Ib/II (in line with CTP and description), added separately as indication specific data publish in separate abstracts. dev status added as per 3930108 and pipeline. 3930108 mentions about specific indications and their current dev status. brand name not added due to translational error. INN added as Bezacitinib. thes request sent to update the thes term and to add missing DCS "Antihaemorrhagics, Antirheumatics". Chemical str and chemical DCS addition request sent. IUPAC and Molecular formula as per info provided by team and Cas not found. Patents info added.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top